search
Back to results

Prevention of Delirium in Inpatients Utilizing Melatonin (PODIUM)

Primary Purpose

Delirium

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Melatonin
Placebo
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Delirium focused on measuring prevention; delirium; in-patients; melatonin,

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Inpatient admission to a general internal medicine service

Exclusion Criteria:

  • expected lifespan or length of stay ≤ 48 hours
  • Non-English speaking
  • Already taking melatonin or ramelteon at the time of randomization
  • Presence of delirium at the time of randomization
  • Unable to take oral medications
  • Subject or proxy unable to provide informed consent within 18 hours of invitation or 24 hours of admission
  • ALT or AST (Liver function tests) > 3 times the upper limit of normal
  • Taking warfarin, nifedipine or fluvoxamine
  • Allergy to melatonin
  • Unable to recall 3 words after distraction by naming the days of the week backwards beginning with Sunday

Sites / Locations

  • Yale New Haven Hospital, Saint Raphael Campus

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Melatonin

Cellulose Microcrystylline

Arm Description

5 mg Melatonin nightly, beginning within 24 hours of admission

Blue capsule matching the melatonin arm

Outcomes

Primary Outcome Measures

Delirium
Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization.

Secondary Outcome Measures

Length of Hospital Stay
Length of stay is defined as the total time hospitalized for the acute illness (in days).
Days Utilizing Restraints
Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization.
Number of Delirium Anti-psychotic Drug Doses Utilized for Delirium During the First 14 Days of Hospitalization.
Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization.

Full Information

First Posted
January 8, 2016
Last Updated
March 10, 2022
Sponsor
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT02654314
Brief Title
Prevention of Delirium in Inpatients Utilizing Melatonin
Acronym
PODIUM
Official Title
Prevention of Delirium in Inpatients Utilizing Melatonin
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Terminated
Why Stopped
Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.
Study Start Date
July 2016 (undefined)
Primary Completion Date
November 3, 2017 (Actual)
Study Completion Date
November 3, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A double blind randomized controlled trial investigating melatonin, 5mg, compared to placebo, given to patients at least 65 years old, admitted to the hospital on a general medical floor, to prevent delirium.
Detailed Description
This study will be a randomized double blind controlled trial, designed to evaluate the efficacy of melatonin in decreasing the incidence of delirium in elderly hospitalized adults compared to a placebo capsule. The study will be conducted on 4 general Internal Medicine inpatient floors at Yale-New Haven Hospital, St. Raphael's campus. Within 24 hours of admission to the floor, study subjects will be approached by a member of the research team, and asked for informed consent. Patients that consent to participate will be randomized to either the treatment or the placebo arm. Each subject will be administered a capsule containing either placebo or 5 mg melatonin each evening at 9 p.m. The capsules will be prepared and administered by the Yale-New haven Hospital Investigational Drug Service. The capsules will be administered nightly until discharge or a maximum of 2 weeks, if the hospitalization is prolonged. Subjects will be assessed twice daily by the floor nurses for evidence of delirium using the Short CAM (Confusion Assessment Method), which is a validated clinical tool for identifying delirium, and the current standard of practice tool for the diagnosis of delirium.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
Keywords
prevention; delirium; in-patients; melatonin,

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
277 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Melatonin
Arm Type
Experimental
Arm Description
5 mg Melatonin nightly, beginning within 24 hours of admission
Arm Title
Cellulose Microcrystylline
Arm Type
Placebo Comparator
Arm Description
Blue capsule matching the melatonin arm
Intervention Type
Drug
Intervention Name(s)
Melatonin
Intervention Description
5 mg Melatonin nightly, beginning within 24 hours of admission
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Cellulose Microcrystylline
Intervention Description
Blue capsule matching the melatonin arm
Primary Outcome Measure Information:
Title
Delirium
Description
Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization.
Time Frame
length of hospitalization, not to exceed 14 days
Secondary Outcome Measure Information:
Title
Length of Hospital Stay
Description
Length of stay is defined as the total time hospitalized for the acute illness (in days).
Time Frame
from day of admission to completion of acute care, not to exceed 30 days
Title
Days Utilizing Restraints
Description
Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization.
Time Frame
length of hospitalization, not to exceed 14 days
Title
Number of Delirium Anti-psychotic Drug Doses Utilized for Delirium During the First 14 Days of Hospitalization.
Description
Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization.
Time Frame
length of hospitalization, not to exceed 14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Inpatient admission to a general internal medicine service Exclusion Criteria: expected lifespan or length of stay ≤ 48 hours Non-English speaking Already taking melatonin or ramelteon at the time of randomization Presence of delirium at the time of randomization Unable to take oral medications Subject or proxy unable to provide informed consent within 18 hours of invitation or 24 hours of admission ALT or AST (Liver function tests) > 3 times the upper limit of normal Taking warfarin, nifedipine or fluvoxamine Allergy to melatonin Unable to recall 3 words after distraction by naming the days of the week backwards beginning with Sunday
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen A Atlas, M.D.
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale New Haven Hospital, Saint Raphael Campus
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
16540616
Citation
Inouye SK. Delirium in older persons. N Engl J Med. 2006 Mar 16;354(11):1157-65. doi: 10.1056/NEJMra052321. No abstract available. Erratum In: N Engl J Med. 2006 Apr 13;354(15):1655.
Results Reference
background
PubMed Identifier
19069020
Citation
Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008 Dec 1;78(11):1265-70.
Results Reference
background
PubMed Identifier
21086534
Citation
de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry. 2010 Dec;25(12):1201-8. doi: 10.1002/gps.2454.
Results Reference
background
PubMed Identifier
25183726
Citation
de Jonghe A, van Munster BC, Goslings JC, Kloen P, van Rees C, Wolvius R, van Velde R, Levi M, de Haan RJ, de Rooij SE; Amsterdam Delirium Study Group. Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. CMAJ. 2014 Oct 7;186(14):E547-56. doi: 10.1503/cmaj.140495. Epub 2014 Sep 2.
Results Reference
background
PubMed Identifier
21189854
Citation
Sultan SS. Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth. 2010 Sep;4(3):169-73. doi: 10.4103/1658-354X.71132.
Results Reference
background
PubMed Identifier
20845391
Citation
Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011 Jul;26(7):687-94. doi: 10.1002/gps.2582. Epub 2010 Sep 15. Erratum In: Int J Geriatr Psychiatry. 2014 May;29(5):550.
Results Reference
background
PubMed Identifier
24554232
Citation
Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014 Apr;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320.
Results Reference
background

Learn more about this trial

Prevention of Delirium in Inpatients Utilizing Melatonin

We'll reach out to this number within 24 hrs